Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor

J Mol Cell Cardiol. 2009 Nov;47(5):576-85. doi: 10.1016/j.yjmcc.2009.06.005. Epub 2009 Sep 18.

Abstract

Stimulation of the beta-adrenergic system is important in the pathological response to sustained cardiac stress, forming the rationale for the use of beta-blockers in heart failure. The beta3-adrenoreceptor (AR) is thought to couple to the inhibitory G-protein, G(i), with downstream signaling through nitric oxide, although its role in the heart remains controversial. In this study, we tested whether lack of beta3-AR influences the myocardial response to pressure-overload. Baseline echocardiography in mice lacking beta3-AR (beta3(-/-)) compared to wild type (WT) showed mild LV hypertrophy at 8 weeks that worsened as they aged. beta3(-/-) mice had much greater mortality after transverse aortic constriction (TAC) than WT controls. By 3 weeks of TAC, systolic function was worse. After 9 weeks of TAC, beta3(-/-) mice also had greater LV dilation, myocyte hypertrophy and enhanced fibrosis. NOS activity declined in beta3(-/-)TAC hearts after 9 weeks, and total and NOS-dependent superoxide rose, indicating heightened oxidative stress and NOS uncoupling. The level of eNOS phosphorylation in beta3(-/-)TAC hearts was diminished, and nNOS and iNOS expression levels were increased. GTP cyclohydrolase-1 expression was reduced, although total BH4 levels were not depleted. 3 weeks of BH4 treatment rescued beta3(-/-) mice from worsened remodeling after TAC, and lowered NOS-dependent superoxide. Thus, lack of beta3-AR signaling exacerbates cardiac pressure-overload induced remodeling and enhances NOS uncoupling and consequent oxidant stress, all of which can be rescued with exogenous BH4. These data suggest a cardioprotective role for the beta3-AR in modulating oxidative stress and adverse remodeling in the failing heart.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Animals
  • Biopterins / analogs & derivatives
  • Biopterins / therapeutic use
  • Blotting, Western
  • Cardiomyopathies / genetics
  • Cardiomyopathies / pathology
  • Echocardiography
  • Hypertrophy, Left Ventricular / drug therapy
  • Hypertrophy, Left Ventricular / genetics*
  • Hypertrophy, Left Ventricular / pathology*
  • Male
  • Mice
  • Mice, Mutant Strains
  • Nitric Oxide Synthase / metabolism
  • Oxidative Stress / genetics
  • Oxidative Stress / physiology
  • Receptors, Adrenergic, beta-3 / genetics
  • Receptors, Adrenergic, beta-3 / physiology*
  • Superoxides / metabolism
  • Vasoconstriction / physiology
  • Ventricular Remodeling / drug effects
  • Ventricular Remodeling / genetics*
  • Ventricular Remodeling / physiology*

Substances

  • Receptors, Adrenergic, beta-3
  • Superoxides
  • Biopterins
  • Nitric Oxide Synthase
  • sapropterin